Aptevo Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

APVO$1.08-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

	For the Three Months Ended March 31,
	2024	2023
Operating Activities
Net (loss) income	$(6,834)	$2,773
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation	719	915
Depreciation and amortization	106	178
Non-cash interest expense and other	—	10
Changes in operating assets and liabilities:
Royalty receivable	—	2,500
Prepaid expenses and other current assets	338	(841)
Operating lease right-of-use asset	115	103
Accounts payable, accrued compensation and other liabilities	(926)	(909)
Long-term operating lease liability	(169)	(163)
Net cash (used in) provided by operating activities	(6,651)	4,566
Investing Activities
Net cash from investing activities	—	—
Financing Activities
Payments of long-term debt, including fees	—	(3,467)
Value of equity awards withheld for tax liability	—	(8)
Proceeds from issuance of common stock	—	1,602
Payments in lieu of fractional shares	(3)	—
Net cash (used in) provided by financing activities	(3)	(1,873)
(Decrease) increase in cash and cash equivalents	(6,654)	2,693
Cash and cash equivalents at beginning of period	16,904	22,635
Cash and cash equivalents at end of period	$10,250	$25,328

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.